https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Systematic Review on the Influence of Tissue Oxygenation on Gut Microbiota and Anastomotic Healing https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42656 Wed 31 Aug 2022 13:02:16 AEST ]]> Comparison of colonic neoplasia detection rates in patients screened inside and outside the national bowel cancer screening program https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38855 Tue 22 Feb 2022 15:26:26 AEDT ]]> A systematic scoping review on natural killer cell function in colorectal cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46186 Tue 15 Nov 2022 08:43:55 AEDT ]]> CD36-a plausible modifier of disease phenotype in familial adenomatous polyposis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43079 Tue 13 Sep 2022 12:12:24 AEST ]]> Does postoperative inflammation or sepsis generate neutrophil extracellular traps that influence colorectal cancer progression? A systematic review https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45013 Thu 27 Oct 2022 17:46:24 AEDT ]]> Tranexamic Acid for Lower GI Hemorrhage: A Randomized Placebo-Controlled Clinical Trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41856 18 years with lower GI hemorrhage requiring hospital admission from November 2011 to January 2014 were screened for trial eligibility (N = 265). INTERVENTIONS: A total of 100 patients were recruited after exclusions and were randomly assigned 1:1 to either tranexamic acid or placebo. MAIN OUTCOME MEASURES: The primary outcome was blood loss as determined by reduction in hemoglobin levels. The secondary outcomes were transfusion rates, transfusion volume, intervention rates for bleeding, length of hospital stay, readmission, and complication rates. RESULTS: There was no difference between groups with respect to hemoglobin drop (11 g/L of tranexamic acid vs 13 g/L of placebo; p = 0.9445). There was no difference with respect to transfusion rates (14/49 tranexamic acid vs 16/47 placebo; p = 0.661), mean transfusion volume (1.27 vs 1.93 units; p = 0.355), intervention rates (7/49 vs 13/47; p = 0.134), length of hospital stay (4.67 vs 4.74 d; p = 0.934), readmission, or complication rates. No complications occurred as a direct result of tranexamic acid use. LIMITATIONS: A larger multicenter trial may be required to determine whether there are more subtle advantages with tranexamic acid use in some of the secondary outcomes. CONCLUSIONS: Tranexamic acid does not appear to decrease blood loss or improve clinical outcomes in patients presenting with lower GI hemorrhage in the context of this trial. see Video Abstract at https://links.lww.com/DCR/A453.]]> Fri 12 Aug 2022 17:04:19 AEST ]]>